Does saturated fat cause heart disease?

Eating less of it lowers the combined risk of cardiovascular events a little, and the effect is clearest when polyunsaturated fat takes its place. A 2020 Cochrane review of 15 randomized trials in 56,675 adults found that cutting saturated fat for at least 2 years lowered combined cardiovascular events by 17%, on moderate quality evidence. In absolute terms, 56 people without heart disease had to cut back for about four years for one of them to avoid an event. The same trials showed little or no effect on deaths.

Established. Cutting saturated fat for two years or more reduces combined cardiovascular events. The Cochrane risk ratio is 0.83 (95% CI 0.70 to 0.98) across 12 trials and 53,758 participants, of whom 8% had an event. A 2024 umbrella review of 21 meta-analyses graded this effect as moderate certainty.

Unsettled. Whether it changes how long people live is not settled. The Cochrane review found little or no effect on death from any cause or from cardiovascular disease. A 2025 meta-analysis of 9 trials and a 2026 meta-analysis of 17 trials also found no clear drop in deaths, and the 2026 one found little or no benefit over 5 years for people at low cardiovascular risk.

People who cut saturated fat for one to avoid a cardiovascular event

Numbers needed to treat from the 2020 Cochrane review. The 17% relative drop means one avoided event for roughly every 56 people who cut back for about four years, and 8% of trial participants had an event at all. The review gives no interval for these numbers, so none is drawn. Source: cards ev-sfhd-01 and ev-sfhd-03 below.

What the trials found

The 2020 Cochrane review is the largest pool of long-term trials. For death from any cause the risk ratio was 0.96 (95% CI 0.90 to 1.03) in 11 trials with 55,858 participants, and for cardiovascular death it was 0.95 (0.80 to 1.12) in 10 trials with 53,421. Both are moderate quality evidence, and both intervals cross 1.0.

Cutting saturated fat, by outcome and by what replaced it

Trials of cutting saturated fatTrials replacing it with polyunsaturated fatObservational data

Below 1.0 means less of the outcome on the lower saturated fat diet, or in the swap named. The first five rows are randomized trials. The last two are observational and cannot show cause. The carbohydrate row is per 5% of calories moved from saturated fat to carbohydrate, of any type. Sources: cards ev-sfhd-01, 02, 06, 08, 12 and 14 below.

What replaces the saturated fat

The swap is where most of the effect seems to sit. A 2010 meta-analysis of 8 trials in 13,614 people, where polyunsaturated fat went up from 5.0% to 14.9% of energy, found coronary events fell by 19% (RR 0.81, 95% CI 0.70 to 0.95). That works out to 10% lower risk for each 5% of energy moved to polyunsaturated fat. In the 2026 meta-analysis, replacing saturated fat with polyunsaturated fat cut nonfatal heart attacks by 25% (RR 0.75, 0.58 to 0.99), a subgroup finding the authors rated as moderate credibility.

Not every swap trial agrees. A 2016 analysis that recovered unpublished data from the Minnesota Coronary Experiment pooled 5 trials in 10,808 people that replaced saturated fat with oil rich in linoleic acid. Cholesterol fell, and death from coronary heart disease did not (HR 1.13, 0.83 to 1.54). These were institutional patients in trials from the late 1960s and early 1970s, testing one kind of oil.

The trials that found nothing

A 2025 meta-analysis of 9 trials in 13,532 people found no significant difference in cardiovascular death (RR 0.94, 0.75 to 1.19), death from any cause (1.01, 0.89 to 1.14) or heart attack (0.85, 0.71 to 1.02). It pooled fewer trials than the Cochrane review and did not analyze combined cardiovascular events, which is the outcome where Cochrane did find an effect. In the 2026 meta-analysis of 17 trials in 66,337 adults, the risk ratios were 0.93 for cardiovascular death, 0.86 for nonfatal heart attack and 0.83 for stroke, and each interval crossed 1.0.

Why cohort studies say something different

Observational data on how much saturated fat people eat find no link with heart disease. A 2010 pooling of 21 cohorts with 347,747 people put the risk ratio for coronary heart disease at 1.07 (0.96 to 1.19), comparing the highest and lowest intakes. A 2014 meta-analysis of 32 observational studies with 530,525 people found 1.02 (0.97 to 1.07) for saturated fat, against 1.16 (1.06 to 1.27) for trans fat. A 2015 review rated the certainty of every saturated fat finding in cohort studies as very low. These studies compare people and cannot show cause, and the 2010 pooling did not account for what people ate instead.

When cohort data are modeled by replacement, a pattern appears. Across 11 cohorts with 344,696 people, moving 5% of calories from saturated to polyunsaturated fat went with 13% fewer coronary events (HR 0.87, 0.77 to 0.97). Moving the same 5% to carbohydrate went with 7% more (HR 1.07, 1.01 to 1.14), and that analysis did not split refined from whole grain carbohydrate.

Who should be careful

The Cochrane review found no evidence that eating less saturated fat caused harm over 2 years or more in 56,675 adults, with little or no effect on cancer, diabetes or blood pressure. Those trials excluded pregnant and breastfeeding women and people who were acutely ill, so they say nothing about them.

Not for everyone. Cutting saturated fat and filling the gap with carbohydrate is the one swap with a signal in the wrong direction. In the pooled cohorts above, coronary events rose by 7% per 5% of calories moved to carbohydrate, an observational association rather than a trial result. WHO's limit covers children as well as adults, and the guideline names fiber-rich whole grains, vegetables, fruits and pulses as the carbohydrate to use.

What expert bodies say

WHO's 2023 guideline strongly recommends that adults and children keep saturated fat to 10% of daily calories, with a conditional recommendation to go further below that. It strongly recommends replacing saturated fat with polyunsaturated fat, and conditionally with monounsaturated fat from plants or with carbohydrates from foods that carry natural fiber. The American Heart Association concluded in a 2017 presidential advisory that lowering saturated fat and replacing it with unsaturated fats, especially polyunsaturated fats, will lower cardiovascular disease. That advisory has no meta-analysis of its own, and the 2025 meta-analysis above found no significant drop in deaths or heart attacks.

How we searched

Searched: a local copy of the PubMed 2026 baseline for saturated fat with cardiovascular, coronary heart and heart disease (922 records, top 40 read by title) and for saturated fat restriction (55 records, top 15 read). Also the local WHO guideline index, a US agency index, Europe PMC for 2025 and 2026 titles (7 records), and web searches for the US Dietary Guidelines and recent meta-analyses. Retraction Watch was checked for every included paper and none was retracted. Search run on 7 October 2026.

Included: the 2020 Cochrane review, meta-analyses of trials from 2010, 2016, 2025 and 2026, a 2024 umbrella review, three meta-analyses of cohort studies, one pooled analysis of 11 cohorts, the 2017 AHA advisory and the 2023 WHO guideline.

Excluded: the earlier version of the Cochrane review, replaced by the 2020 update with corrected numbers. A cohort meta-analysis on mortality that overlapped the included ones. A 2025 European scientific statement that mentions saturated fat only in a list. Two commentaries without new data, a Mendelian randomization study on stroke, and studies of fatty acid chain length and biomarkers.

What we read: abstracts and the WHO guideline text. The 2025 meta-analysis was outside the local corpus, and its quotation was confirmed by a second, independent request by DOI.

What we could not get: the full text of the 2020 Cochrane review, which is not in PubMed Central. The verbatim text of the Dietary Guidelines for Americans 2025 to 2030, which secondary sources say keeps the 10% limit. The EFSA reference values for fats were not fetched in this run.

What would change this answer

New long-term trials that replace saturated fat with polyunsaturated fat in people who already take statins. The authors of the 2025 meta-analysis call for exactly these trials.
Pooled individual patient data split by baseline risk. The 2026 meta-analysis began this and found little or no benefit at low risk over 5 years. A clear absolute estimate for people at high risk would settle who gains most.
Cohort studies that separate refined from whole grain carbohydrate as the replacement. The 7% rise in coronary events with carbohydrate cannot be read further until that split exists.

The rest of the nutrient, in one place. Fat: how much to eat, and which kind matters for your heart → What it does, how much you need, who runs short, and what too much does, with the evidence level shown on every line.

The full guide

Fat: how much to eat, and which kind matters for your heart

The same question for other foods (heart health)

Sources

ev-sfhd-01 · Meta-analysis or systematic review · systematic review and random-effects meta-analysis of RCTs · n = 56675
The included long-term trials suggested that reducing dietary saturated fat reduced the risk of combined cardiovascular events by 17% (risk ratio (RR) 0.83; 95% confidence interval (CI) 0.70 to 0.98, 12 trials, 53,758 participants of whom 8% had a cardiovascular event, I² = 67%, GRADE moderate-quality evidence).
Who: adults with or without cardiovascular disease in RCTs of at least 24 months that reduced saturated fat
Effect: combined cardiovascular events RR 0.83 (95% CI 0.70 to 0.98); 12 trials, 53,758 participants; I2 67%; GRADE moderate
Certainty: Cochrane, version pub3 (August 2020) replaces pub2 (RR 0.79). Greater SFA reduction means greater reduction in events (meta-regression).
Cochrane Database Syst Rev, 2020 · checked 2026-10-07 · we read the abstract
ev-sfhd-02 · Meta-analysis or systematic review · systematic review and random-effects meta-analysis of RCTs · n = 55858
We found little or no effect of reducing saturated fat on all-cause mortality (RR 0.96; 95% CI 0.90 to 1.03; 11 trials, 55,858 participants) or cardiovascular mortality (RR 0.95; 95% CI 0.80 to 1.12, 10 trials, 53,421 participants), both with GRADE moderate-quality evidence.
Who: adults in long-term RCTs of reduced saturated fat
Effect: all-cause mortality RR 0.96 (95% CI 0.90 to 1.03), 11 trials; cardiovascular mortality RR 0.95 (0.80 to 1.12), 10 trials, 53,421 participants; GRADE moderate
Certainty: Events decrease, mortality does not; MI, stroke, and CHD events separately: very low certainty.
Cochrane Database Syst Rev, 2020 · checked 2026-10-07 · we read the abstract
ev-sfhd-03 · Meta-analysis or systematic review · systematic review and random-effects meta-analysis of RCTs · n = 56675
The number needed to treat for an additional beneficial outcome (NNTB) was 56 in primary prevention trials, so 56 people need to reduce their saturated fat intake for ~four years for one person to avoid experiencing a CVD event.
Who: adults in primary and secondary prevention RCTs of reduced saturated fat
Effect: NNTB 56 in primary prevention over about 4 years; NNTB 53 in secondary prevention
Certainty: NNT from the pub3 abstract; the effect did not depend on sex, duration or baseline risk (relative).
Cochrane Database Syst Rev, 2020 · checked 2026-10-07 · we read the abstract
ev-sfhd-04 · Meta-analysis or systematic review · systematic review and random-effects meta-analysis of RCTs · n = 56675
There was no evidence of harmful effects of reducing saturated fat intakes.
Who: adults (not acutely ill, pregnant or breastfeeding) in RCTs of at least 24 months
Effect: no harmful effects found; little or no effect on cancer mortality, cancer diagnoses, diabetes, HDL, triglycerides or blood pressure
Certainty: Pregnant and breastfeeding women and the acutely ill were excluded: there are no data for them.
Cochrane Database Syst Rev, 2020 · checked 2026-10-07 · we read the abstract
ev-sfhd-05 · Meta-analysis or systematic review · systematic review and random-effects meta-analysis of RCTs · n = 66337
CONCLUSION: For persons at low cardiovascular risk, reducing or modifying saturated fat intake has little or no benefit over a period of 5 years.
Who: adults with or without cardiovascular disease in RCTs reducing or modifying saturated fat, searched to July 2025
Effect: all-cause mortality RR 0.96 (0.88 to 1.06); cardiovascular mortality RR 0.93 (0.77 to 1.11); nonfatal MI RR 0.86 (0.70 to 1.06); stroke RR 0.83 (0.58 to 1.19); low to moderate certainty
Certainty: The newest synthesis of RCTs; absolute effects are stratified by risk (thresholds 5 and 10 per 1000 over 5 years).
Ann Intern Med, 2026 · checked 2026-10-07 · we read the abstract
ev-sfhd-06 · Meta-analysis or systematic review · systematic review and random-effects meta-analysis of RCTs · n = —
The effects were more pronounced when replacing saturated fat with polyunsaturated fat for nonfatal MI (RR, 0.75 [CI, 0.58 to 0.99]; P for interaction = 0.05; moderate credibility of subgroup effect based on Instrument to assess the Credibility of Effect Modification Analyses assessments).
Who: adults in RCTs where saturated fat was replaced with polyunsaturated fat
Effect: nonfatal MI RR 0.75 (95% CI 0.58 to 0.99); P for interaction 0.05; moderate credibility of subgroup effect
Certainty: Subgroup; data on replacement with MUFA or protein are limited.
Ann Intern Med, 2026 · checked 2026-10-07 · we read the abstract
ev-sfhd-07 · Meta-analysis or systematic review · systematic review and random-effects meta-analysis of RCTs · n = 13532
No significant differences in cardiovascular mortality (relative risk [RR] = 0.94, 95% confidence interval [CI]: 0.75-1.19), all-cause mortality (RR = 1.01, 95% CI: 0.89-1.14), myocardial infarction (RR = 0.85, 95% CI: 0.71-1.02), and coronary artery events (RR = 0.85, 95% CI: 0.65-1.11) were observed between the intervention and control groups.
Who: participants in 9 RCTs of saturated fat reduction (2 primary, 7 secondary prevention), searched to April 2023
Effect: cardiovascular mortality RR 0.94 (0.75 to 1.19); all-cause mortality RR 1.01 (0.89 to 1.14); MI RR 0.85 (0.71 to 1.02); coronary events RR 0.85 (0.65 to 1.11)
Certainty: Outside the corpus; fewer RCTs per Cochrane (without a combined CVD events endpoint). Authors: "cannot be recommended", which diverges from WHO/AHA.
JMA Journal, 2025 (Yamada et al.) · checked 2026-10-07 · we read the abstract
ev-sfhd-08 · Meta-analysis or systematic review · systematic review and random-effects meta-analysis of RCTs · n = 13614
The overall pooled risk reduction was 19% (RR = 0.81, 95% confidence interval [CI] 0.70-0.95, p = 0.008), corresponding to 10% reduced CHD risk (RR = 0.90, 95% CI = 0.83-0.97) for each 5% energy of increased PUFA, without evidence for statistical heterogeneity (Q-statistic p = 0.13; I(2) = 37%).
Who: participants randomized to increased PUFA replacing SFA for at least 1 year; PUFA 14.9% vs 5.0% of energy
Effect: CHD events RR 0.81 (95% CI 0.70 to 0.95); RR 0.90 (0.83 to 0.97) per 5% energy of PUFA
Certainty: Includes old RCTs, some with incomplete publication (see MCE, 27071971).
PLoS Med, 2010 · checked 2026-10-07 · we read the abstract
ev-sfhd-09 · Meta-analysis or systematic review · systematic review and random-effects meta-analysis of RCTs · n = 10808
In meta-analyses, these cholesterol lowering interventions showed no evidence of benefit on mortality from coronary heart disease (1.13, 0.83 to 1.54) or all cause mortality (1.07, 0.90 to 1.27).
Who: RCTs replacing saturated fat with vegetable oil rich in linoleic acid without other interventions, including the recovered Minnesota Coronary Experiment
Effect: CHD mortality HR 1.13 (0.83 to 1.54); all-cause mortality 1.07 (0.90 to 1.27)
Certainty: Recovered unpublished MCE data (1968-73), institutionalized patients; a narrow question: linoleic acid only.
BMJ, 2016 · checked 2026-10-07 · we read the abstract
ev-sfhd-10 · Meta-analysis or systematic review · umbrella review of meta-analyses of RCTs and cohort studies · n = 21 meta-analyses
The effect of reduction in SAF intake on combined cardiovascular events (RR 0.79, 95%CI 0.66-0.93) was graded as having moderate certainty of evidence.
Who: adults in meta-analyses of RCTs (3) and cohort studies (18), 2012 to 2022
Effect: combined cardiovascular events RR 0.79 (0.66 to 0.93), moderate certainty; no effect on all-cause or cardiovascular mortality
Certainty: RR 0.79 taken from Cochrane pub2; the newer pub3 gives 0.83.
Front Public Health, 2024 · checked 2026-10-07 · we read the abstract
ev-sfhd-11 · Observational data · meta-analysis of prospective cohort studies · n = 347747
The pooled relative risk estimates that compared extreme quantiles of saturated fat intake were 1.07 (95% CI: 0.96, 1.19; P = 0.22) for CHD, 0.81 (95% CI: 0.62, 1.05; P = 0.11) for stroke, and 1.00 (95% CI: 0.89, 1.11; P = 0.95) for CVD.
Who: 347,747 subjects followed 5 to 23 years in prospective cohort studies; 11,006 developed CHD or stroke
Effect: highest vs lowest intake: CHD RR 1.07 (0.96 to 1.19); stroke 0.81 (0.62 to 1.05); CVD 1.00 (0.89 to 1.11)
Certainty: Observational data; does not account for what was used to replace SFA.
Am J Clin Nutr, 2010 · checked 2026-10-07 · we read the abstract
ev-sfhd-12 · Observational data · systematic review and meta-analysis of observational studies and RCTs · n = 530525
In observational studies, relative risks for coronary disease were 1.02 (95% CI, 0.97 to 1.07) for saturated, 0.99 (CI, 0.89 to 1.09) for monounsaturated, 0.93 (CI, 0.84 to 1.02) for long-chain ω-3 polyunsaturated, 1.01 (CI, 0.96 to 1.07) for ω-6 polyunsaturated, and 1.16 (CI, 1.06 to 1.27) for trans fatty acids when the top and bottom thirds of baseline dietary fatty acid intake were compared.
Who: participants in prospective observational studies of dietary fatty acids, top vs bottom thirds of intake
Effect: saturated RR 1.02 (0.97 to 1.07); trans fatty acids RR 1.16 (1.06 to 1.27)
Certainty: Level C, because the figure is from the observational part of the review; the RCTs there are about PUFA supplements, not about lowering SFA.
Ann Intern Med, 2014 · checked 2026-10-07 · we read the abstract
ev-sfhd-13 · Observational data · meta-analysis of prospective cohort studies · n = 339090
The certainty of associations between saturated fat and all outcomes was "very low."
Who: prospective cohort studies, 5 to 17 comparisons with 90,501 to 339,090 participants per outcome
Effect: total CHD RR 1.06 (0.95 to 1.17); CVD mortality 0.97 (0.84 to 1.12); CHD mortality 1.15 (0.97 to 1.36); GRADE very low
Certainty: GRADE very low for all SFA outcomes; for trans fats there is an association.
BMJ, 2015 · checked 2026-10-07 · we read the abstract
ev-sfhd-14 · Observational data · pooled analysis of 11 prospective cohort studies · n = 344696
For a 5% lower energy intake from SFAs and a concomitant higher energy intake from carbohydrates, there was a modest significant direct association between carbohydrates and coronary events (hazard ratio: 1.07; 95% CI: 1.01, 1.14); the hazard ratio for coronary deaths was 0.96 (95% CI: 0.82, 1.13).
Who: 344,696 persons in 11 American and European cohorts, 4 to 10 years of follow-up
Effect: SFA to PUFA: coronary events HR 0.87 (0.77 to 0.97), coronary deaths 0.74 (0.61 to 0.89); SFA to carbohydrates: coronary events HR 1.07 (1.01 to 1.14)
Certainty: Observational substitution model; carbohydrate type not separated.
Am J Clin Nutr, 2009 · checked 2026-10-07 · we read the abstract
ev-sfhd-15 · Position of an expert body · scientific advisory of a professional society · n = —
Taking into consideration the totality of the scientific evidence, satisfying rigorous criteria for causality, we conclude strongly that lowering intake of saturated fat and replacing it with unsaturated fats, especially polyunsaturated fats, will lower the incidence of CVD.
Who: general population
Effect: lowering saturated fat and replacing it with unsaturated, especially polyunsaturated, fats will lower CVD incidence (advisory conclusion)
Certainty: Society position without its own MA; diverges from the 2025 MA (40416032) and cohort reviews.
Circulation, 2017 · checked 2026-10-07 · we read the abstract
ev-sfhd-16 · Position of an expert body · WHO guideline · n = —
WHO recommends that adults and children reduce saturated fatty acid intake to 10% of total energy intake (strong recommendation).
Who: adults and children
Effect: limit saturated fat to 10% of total energy (strong); further below 10% (conditional)
Certainty: A limit, not a UL; DGA 2025-2030 also has 10% (per secondary sources, verbatim not obtained).
WHO guideline: Saturated fatty acid and trans-fatty acid intake for adults and children, 2023 · checked 2026-10-07 · we read the section
ev-sfhd-17 · Position of an expert body · WHO guideline · n = —
WHO recommends replacing saturated fatty acids in the diet with polyunsaturated fatty acids (strong recommendation), monounsaturated fatty acids from plant sources (conditional recommendation), or carbohydrates from foods containing naturally occurring dietary fibre, such as whole grains, vegetables, fruits and pulses (conditional recommendation).
Who: adults and children
Effect: replace with PUFA (strong); plant MUFA or fiber-containing carbohydrates (conditional)
Certainty: Consistent with the substitution cards (20351774, 41397264, 19211817).
WHO guideline: Saturated fatty acid and trans-fatty acid intake for adults and children, 2023 · checked 2026-10-07 · we read the section

How this page was made. Evidence was extracted from primary sources into cards, every number was re-checked against the source, and the text was written from those cards. Bioma Learn has no human medical reviewer at this time, and we say so rather than invent one. Methodology. This is information, not medical advice.